Compositions and Methods for Inhibiting Viral Adhesion

• US 20070184065A1
• Filed: 01/26/2007
• Published: 08/09/2007
• Est. Priority Date: 01/26/2006
• Status: Abandoned Application

• Current Assignee: Recopharma AB
• Original Assignee: Recopharma AB
• Inventors: Holgersson, Jan
• Application Number:
  US11/627,548
• Publication Number:
  US 20070184065A1
• Time in Patent Office: Days
• US Class Current: 424/186.100
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07K 14/4727 Mucins, e.g. human intestinal mucin
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 2796/00 Viruses not covered by groups C12N2710/00 - C12N2795/00
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention provides compositions and methods for treating or preventing viral infections.

Claims

1. A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide wherein the first polypeptide carries at least one glycan selected from the group consisting of:

a) a Siaα

3Galβ

4GlcNAcβ

glycan,

b) a Siaα

3Galβ

3GlcNAcβ

glycan,

c) a Siaα

6Galβ

4GlcNAcβ

glycan,

d) a Siaα

6Galβ

3GlcNAcβ

glycan,

e) a Fucα

2Galβ

3GalNAcα

glycan

f) a Fucα

2Galβ

3GlcNAcβ

glycan and

g) a Fucα

2Galβ

4GlcNAcβ

glycan,

and the second polypeptide comprises at least a region of an immunoglobulin polypeptide.

2. The fusion polypeptide of claim 1, wherein the first polypeptide is a mucin polypeptide.

3. The fusion polypeptide of claim 1, wherein said glycan is terminal.

4. The fusion polypeptide of claim 1, wherein said glycan is multivalent.

5. The fusion polypeptide of claim 2, wherein the mucin is selected from the group consisting of PSGL-1, MUC1, MUC2, MUC3, MUC4, MUC5a, MUC5b, MUC5c, MUC6, MUC11, MUC12, CD34, CD43, CD45, CD96, GlyCAM-1, MAdCAM, or a fragment thereof

6. The fusion polypeptide of claim 2, wherein said mucin polypeptide comprises at least a region of a P-selectin glycoprotein ligand-1.

7. The fusion polypeptide of claim 2, wherein said mucin polypeptide includes an extracellular portion of a P-selectin glycoprotein ligand-1.

8. The fusion polypeptide of claim 1, wherein the first polypeptide is an alpha glycoprotein polypeptide.

9. The fusion polypeptide of claim 1, wherein the first polypeptide comprises at least a region of an alpha-1-acid glycoprotein.

10. The fusion polypeptide of claim 1, wherein the second polypeptide comprises a region of a heavy chain immunoglobulin polypeptide.

11. The fusion polypeptide of claim 1, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

12. A method of decreasing adhesion of a virus to a cell, comprising contacting the virus with the fusion polypeptide of claim 1.

13. A method of preventing viral or alleviating a symptom of viral infection in a subject in need thereof comprising administering to the subject the fusion polypeptide of claim 1.

14. The method of claim 12 or 13, wherein the virus is an oculotropic virus, a human influenza virus, an avian influenza virus, a recombination of a human and an avian influenza virus, or a Norovirus.

15. The method of claim 14, wherein said oculotrophic virus is an adenovirus 37, an enterovirus 70 or an avian influenza virus.

16. A cell genetically engineered to produce the fusion polypeptide of claim 1.